Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 2,387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D

NCT04335513
View directory record Official record
Conditions
Type 1 Diabetes, Prediabetic State, Dysglycemia, Autoimmune Diabetes
Interventions
Early CGM-guided education and initiation of insulin therapy., Usual care: glucometer surveillance and basic education.
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 20 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 29, 2026, 1:40 AM EDT
Terminated Not applicable Interventional

Two Anger Management Programs for Teens.

NCT02001246
View directory record Official record
Conditions
Anger, Hostility, Aggression
Interventions
Real Deal program for Anger Management, Mind-body Bridging (MBB) program
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
13 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Not applicable Interventional Results available

Preventing Persistent Post-Surgical Pain and Dysfunction

NCT03965897
View directory record Official record
Conditions
Pain, Function, Anxiety, Depression, Arthroplasty, Replacement, Knee, Veterans
Interventions
Acceptance and Commitment Therapy (ACT), Attention Control (AC)
Behavioral · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Phase 2 Interventional Results available

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

NCT03694262
View directory record Official record
Conditions
Endometrial Cancer, Uterine Carcinosarcoma
Interventions
Rucaparib, Bevacizumab, Atezolizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
New York, New York • Bethlehem, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

NCT06292923
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Foralumab, Placebo
Drug · Other
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
North Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Phase 1 Interventional

α-TEA in Advanced Cancer

NCT02192346
View directory record Official record
Conditions
Metastatic Carcinoma, Metastatic Sarcoma, Metastatic Lymphoma
Interventions
2.4 mg/kg α-TEA, 4.8 mg/kg α-TEA, 8.0 mg/kg α-TEA, 9.6 mg/kg α-TEA, 12 mg/kg α-TEA, 16.8 mg/kg α-TEA, 19.2 mg/kg α-TEA, 22.3 mg/kg α-TEA, 26.8 mg/kg α-TEA
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Clackamas, Oregon • Newberg, Oregon • Oregon City, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 29, 2026, 1:40 AM EDT
Not yet recruiting Phase 1 Interventional

Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer

NCT07732413
View directory record Official record
Conditions
Progressive Pediatric Brain Cancer
Interventions
NLG802 (indoximod Prodrug), Temozolomide
Drug
Lead sponsor
Lumos Pharma
Industry
Eligibility
5 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Recruiting Phase 2 Interventional

Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

NCT07265596
View directory record Official record
Conditions
Prodromal Parkinsons Disease
Interventions
[18F] AV-133 PET Imaging
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 29, 2026, 1:40 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia

NCT04486586
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Active tDCS plus Speech-Language Therapy, Sham plus Speech-Language Therapy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 29, 2026, 1:40 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma

NCT02062827
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
Interventions
M032 (NSC 733972)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 29, 2026, 1:40 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

NCT03530397
View directory record Official record
Conditions
Selected Advanced Solid Tumors
Interventions
MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Recruiting Not applicable Interventional

High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV

NCT05965518
View directory record Official record
Conditions
HIV, Arterial Stiffness, Cognitive Dysfunction
Interventions
High-Intensity Interval Training, Continuous Moderate Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Phase 4 Interventional Results available

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

NCT01496313
View directory record Official record
Conditions
Thyroid Cancer
Interventions
300mg vandetanib, 150mg vandetanib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 29, 2026, 1:40 AM EDT
Recruiting Not applicable Interventional

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

NCT06101290
View directory record Official record
Conditions
Prostate Cancer, Oligoprogressive, Urothelial Carcinoma, Renal Cell Carcinoma
Interventions
Ablative local therapy
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Recruiting Early Phase 1 Interventional

Propranolol in Primary Progressive Aphasia

NCT06066710
View directory record Official record
Conditions
Aphasia, Primary Progressive
Interventions
Propranolol, Magnetic Resonance Imaging (MRI), Placebo
Drug · Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Not listed No phase listed Observational

Patient-Reported Outcome Study of Project ECHO for ILD

NCT05450276
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Not applicable Interventional

Volume,Sodium and Blood Pressure Management in HD

NCT01766882
View directory record Official record
Conditions
End Stage Renal Failure
Interventions
Lower sodium intervention, Progressive Challenge to Post Dialysis Weight
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Phase 2 Interventional Results available

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

NCT00913835
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Olaratumab, liposomal doxorubicin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Joliet, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Phase 2 Interventional Results available

Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas

NCT01497860
View directory record Official record
Conditions
Low-grade Glioma
Interventions
Vinorelbine
Drug
Lead sponsor
Eugene Hwang
Other
Eligibility
Up to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

NCT00974311
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 29, 2026, 1:40 AM EDT
Recruiting No phase listed Observational

Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia

NCT07732907
View directory record Official record
Conditions
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
Lawrenceville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Phase 4 Interventional Results available

Novartis Everolimus Transition

NCT02096107
View directory record Official record
Conditions
Graft Dysfunction, Interstitial Fibrosis
Interventions
Everolimus, Standard of Care
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 29, 2026, 1:40 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

NCT00695292
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
irinotecan, Carboplatin, sunitinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Fort Myers, Florida • Orlando, Florida • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 29, 2026, 1:40 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

NCT04088500
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 29, 2026, 1:40 AM EDT